All In Biotech

Drug Trial Radar · NCT07309562

The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age

A Multicenter, Randomized, Open-Label, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Inpegsomatropin Injection, s.c Once a Week, Compared With Recombinant Human Growth Hormone (rhGH) Injection in Children With Short Stature Born Small for Gestational Age(SGA)

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 141 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

141

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Mar 2028

Study completion May 7, 2028

Sponsor

Sponsor type
Industry
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection,once a week,compared with recombinant human growth hormone (rhGH) in children with short stature born small for gestational age (SGA).It plans to enroll 141 children with short stature born small for gestational age (SGA), who will be stratified by gender and age and randomized in a 1:1:1 ratio to either Experimental Group 1, Experimental Group 2, or the Active Control Group. All participants will undergo a screening period (up to 12 weeks), a treatment period (52 weeks), and a post-treatment follow-up period (5 weeks). Safety and efficacy will be comprehensively evaluated.

Conditions

  • Small for Gestational Age

Interventions

  • Inpegsomatropin InjectionDrug

    Inpegsomatropin injection, 140 μg/kg/week, s.c., once weekly, for 52 weeks.

  • Inpegsomatropin InjectionDrug

    Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly, for 52 weeks.

  • Recombinant Human Growth Hormone InjectionDrug

    Recombinant human growth hormone injection, 0.033mg/kg/day, s.c.,once daily, for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Growth velocity (HV, cm/year).Time frame: Week 52

Locations

49 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • Hunan Children's Hospital

    Changsha, China · Recruiting

  • Chengdu Women's and Children's Central Hospital

    Chengdu, China · Recruiting

  • West China Second University Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Children's Hospital of Chongqing Medical University

    Chongqing, China · Recruiting

  • Fuzhou First General Hospital

    Fuzhou, China · Recruiting

  • Guangzhou Women and Children's Medical Center, Guangzhou Medical University

    Guangzhou, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China · Recruiting

  • Hainan Women and Children's Medical Center

    Haikou, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Heilongjiang Provincial Hospital

    Harbin, China · Recruiting

  • Anhui Children's Hospital

    Hefei, China · Recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Inner Mongolia People's Hospital

    Hohhot, China · Recruiting

  • Shandong Provincial Hospital

    Jinan, China · Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, China · Recruiting

  • Jiujiang Maternal and Child Health Hospital

    Jiujiang, China · Recruiting

  • Kunming Children's Hospital

    Kunming, China · Recruiting

  • Gansu Provincial Maternity and Child-care Hospital (Gansu Provincial Central Hospital)

    Lanzhou, China · Recruiting

  • Liuzhou People's Hospital

    Liuzhou, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China · Recruiting

  • Jiangxi Provincial Children's Hospital

    Nanchang, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Nanjing Children's Hospital

    Nanjing, China · Recruiting

  • Ningbo Women and Children's Hospital, Ningbo University

    Ningbo, China · Recruiting

  • Qujing Maternal and Child Health Hospital

    Qujing, China · Recruiting

  • Sanya Central Hospital (Hainan Third People's Hospital)

    Sanya, China · Recruiting

  • Shanghai Children's Hospital

    Shanghai, China · Recruiting

  • Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, China · Recruiting

  • Children's Hospital of Soochow University

    Suzhou, China · Recruiting

  • Tianjin Medical University General Hospital

    Tianjin, China · Recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, China · Recruiting

  • The Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.